Please join our staff as we participate or present in the following oral and poster presentations at the 2017 ASCO Annual Meeting
Saturday, June 3
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
8:00 AM – 9:15 AM
Location: S404
EDUCATION SESSION: mHealth: Mobile Technologies to Virtually Bring the Patient into Oncology Practice
8:00 AM – 8:20 AM
Technological Solutions to Improve Efficiency
Nathan A. Pennell, MD, PhD – Speaker
8:00 AM – 11:30 AM
Location: Hall A
POSTER SESSION: Gastrointestinal (Noncolorectal) Cancer
Abstract TPS4152: SWOG S1505: A randomized phase II study of perioperative mFOLFIRINOX vs. gemcitabine/nab-paclitaxel as therapy for resectable pancreatic adenocarcinoma
Poster Board: #133b
Davendra Sohal, MD, MPH – First Author
8:45 AM – 9:30 AM
Location: Member Lounge Room S501
TRAINEE & EARLY CAREER ONCOLOGIST
Contract Negotiations
Jame Abraham, MD
1:15 PM – 4:45 PM
Location: Hall A
POSTER SESSION: Tumor Biology
Abstract 11518: Changes in computer extracted features of vessel tortuosity on CT scans post-treatment in responders compared to non-responders for non-small cell lung cancer on immunotherapy
Poster Board: #218
Discussed at the Poster Discussion Session on Saturday, June 3, 2017, 4:45 PM – 6:00 PM, at S406
Vamsidhar Velcheti, MD – First Author
Abstract 11547: Pre-treatment hematological markers as a predictive biomarker for survival in patients with non-small cell lung cancer treated with nivolumab
Poster Board: #247
Pradnya Dinkar Patil, MD – First Author
Abstract 11552: Tetrahydrouridine-decitabine for non-cytotoxic epigenetic therapy of NSCLC to enhance immunotherapeutic effect of anti-PD1 in vivo
Poster Board: #252
Kai Kang, PhD – First Author
Abstract 11566: Computer extracted measurements of vessel tortuosity on baseline CT scans to predict response to nivolumab immunotherapy for non-small cell lung cancer
Poster Board: #266
Monica Khunger, MD – First Author
1:15 PM – 4:45 PM
Location: Hall A
POSTER SESSION: Patient and Survivor Care
Abstract 10063: What do social media-savvy cancer survivors tell us about the completeness of survivorship care plans?
Poster Board: #52
Diane Mary Radford, MD, FACS, FRCSEd – First Author
3:00 PM – 4:15 PM
Location: Hall D2
POSTER DISCUSSION SESSION: Lung Cancer—Non-Small Cell Metastatic
3:18 PM – 3:30 PM
Three Faces of IO: Efficacy, Toxicity, Cost
Vamsidhar Velcheti, MD – Discussant
Discussing Abstract(s): 9011, 9012, 9013
Timing and type of side effects differ greatly from chemotherapy
Dedicated multidisciplinary teams support 84 ultra-rare cancers
Sessions explore treatment advances and multidisciplinary care
New research from Cleveland Clinic helps explain why these tumors are so refractory to treatment, and suggests new therapeutic avenues
Combination of olaparib and carboplatin results in complete durable response for a patient with BRCA2 and “BRCAness” mutations
Early communication between oncologists and ophthalmologist warranted
Case-based course delves into latest treatment approaches
Long-term relationship building and engagement key to gaining community trust